MedTrace Logo

A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma

NCT03778957 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 724

Last updated 2026-04-15

No results posted yet for this study

Summary

A global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab and bevacizumab therapy in patients with locoregional hepatocellular carcinoma

Conditions

Interventions

DRUG

Durvalumab

Durvalumab IV (intravenous)

DRUG

Bevacizumab

Bevacizumab IV (intravenous)

OTHER

Placebo

Saline solution for Durvalumab and/or Bevacizumab masking (IV intravenous)

PROCEDURE

Transarterial Chemoembolization (TACE)

TACE (chemo and embolic agent injection into the hepatic artery)

Sponsors & Collaborators

Principal Investigators

  • Bruno Sangro, MD · Clinica Universidad de Navarra

  • Riccardo Lencioni, MD FSIR EBIR · University of Pisa / Miami Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
110 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-30
Primary Completion
2023-09-11
Completion
2026-08-31
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Brazil
  • Canada
  • China
  • France
  • Hong Kong
  • India
  • Italy
  • Japan
  • Mexico
  • Russia
  • Singapore
  • South Korea
  • Spain
  • Taiwan
  • Thailand
  • Vietnam

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03778957 on ClinicalTrials.gov